Minor Changes and the 10-Day Implicit Approval Rule in Tanzania

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Tanzania applies a minor change mechanism based on implicit approval. TMDA/DMD/MDA/G/003 §3.2 states, in the official wording:

Applicants must satisfy themselves that they meet all of the prescribed conditions for the change and submit all required documentation with the application for change. Such changes can be implemented if the Authority has not issued objection letter within 10 days from the date of acknowledgement of receipt. Should queries arise during the specified period; then the change can only be implemented on receipt of a letter of acceptance from the Authority.

The provision can be broken down into three rules:

  1. The applicant bears the responsibility for compliance confirmation – the applicant must be satisfied of meeting all prescribed conditions for the change and must submit all required documentation.
  2. 10-day implicit approval – counted from the date of acknowledgement of receipt by TMDA, the change may be implemented if no objection letter is received within 10 days.
  3. Queries block implementation – if queries are received during those 10 days, the change may only be implemented after a letter of acceptance from TMDA is received.

Together these rules create a middle tier between major changes (which always require affirmative approval) and notifiable changes (which need no approval at all). The practical burden falls on documentation discipline: the applicant must be able to prove both the self-assessment and the passage of the 10-day period, and the clock is controlled by TMDA’s acknowledgement, not by the applicant’s submission behaviour.

2. Legal basis

InstrumentReferencePublication dateProvisions
Guidelines on Submission of Application for Change(s) to Approved Medical Devices and In-Vitro DiagnosticsTMDA/DMD/MDA/G/003, Rev. 00, First EditionJune 2022§3.2 (Minor changes), §3.1 (Major changes), §3.3 (Notifiable changes)
The Tanzania Food, Drugs and Cosmetics (Control of Medical Devices) Regulations, 2015GN. No. 31531 July 2015Articles 23(1), 23(2), 23(3)
The Tanzania Medicines and Medical Devices (Fees and Charges) Regulations, 2022Fees Regulations (2022)2022Minor variation: medical devices 150 USD / IVD 200 USD, processing 10 days

3. Expert insights

Insight 1: The starting point is the date of acknowledgement of receipt, not the date of submission.

§3.2 uses the wording from the date of acknowledgement of receipt. In practice, an online portal submission generates an acknowledgement, and the 10 days run from that date. The acknowledgement must be retained, because without it the applicant cannot prove that the 10 days have expired. GRZAN’s practice is to archive the acknowledgement screenshot together with its timestamp so that the implementation decision can always be traced to documentary evidence.

Insight 2: Implicit approval is conditional on the applicant being satisfied that all conditions are met – a self-assessment duty.

The first sentence of §3.2 places the compliance confirmation duty expressly on the applicant. This means that even if TMDA issues no objection letter within 10 days, an erroneous self-assessment can still lead to the change being found to have been implemented without approval. Implicit approval is not a transfer of responsibility: the silence of the Authority validates only a change that was properly classified and properly documented at the outset.

Insight 3: The contrast with major changes shows the value of this mechanism.

§3.1 provides that major changes should not be implemented unless they have official approval from the Authority, with a letter of acceptance issued where they are acceptable. §3.2 allows minor changes to be implemented after 10 days without objection. The difference lies in whether affirmative approval is required. The minor change route therefore trades a formal approval step for a waiting period plus a self-assessment burden, which is often faster overall but demands stronger internal documentation.

Insight 4: The 10 days of §3.2 and the 10-day processing time in the fee schedule are two different concepts that happen to share a number.

In the fee schedule on the TMDA website, the processing time for minor variation (medical devices 150 USD, IVD 200 USD) is stated as 10 days; the 10 days in §3.2 are an objection period. The two figures coincide but differ in nature: one is the Authority’s processing time, the other is the applicant’s waiting period. They should not be conflated in project planning, because the fee-schedule figure does not create any right of implementation.

Insight 5: Notifiable changes require no waiting at all.

§3.3 provides that notifiable changes may be implemented by the manufacturer without prior approval from the Authority, but should be reported upon completion of their implementation. The three categories thus form a complete gradient: major (affirmative approval required), minor (10-day implicit approval), notifiable (report after implementation). Correct classification is what determines which waiting regime, if any, applies to a given change.

4. Practical recommendations

  1. Use the date of acknowledgement of receipt as the starting point of the clock and retain the portal acknowledgement screenshot and timestamp.
  2. Do not implement before the 10 days expire, even where the perceived risk is very low.
  3. Run a dual self-check on conditions and documents before submission – §3.2 places the confirmation duty on the applicant.
  4. Suspend implementation upon receiving queries and wait for the letter of acceptance.
  5. Manage the three categories on the gradient: major awaits the acceptance letter, minor waits 10 days, notifiable is reported after implementation.
  6. Record three items in the change register: the starting point of the clock, the expiry date, and whether an objection letter was received.

5. Verification checklist

  • □ The acknowledgement of receipt from TMDA has been obtained and archived (starting point of the clock).
  • □ The dual self-check on all conditions and all documents was completed before submission.
  • □ The full 10 days elapsed and no objection letter was received before implementation.
  • □ Where queries were received, implementation was switched to waiting for the letter of acceptance.
  • □ The change register records the starting point, the expiry date and the objection letter status.
  • □ The 10-day objection period of §3.2 has been distinguished from the 10-day processing time in the fee schedule.

Regulatory information verified as of 29 October 2026. All provisions cited in this document were checked against the official texts published by TMDA (TMDA/DMD/MDA/G/003 §3.1, §3.2, §3.3; GN. No. 315, Article 23; the TMDA website fee schedule); the review is repeated whenever the regulations are updated.

  • Tanzania local resources: GRZAN can coordinate licensed local responsible person (LRP) and distributor resources covering online submission, sample delivery, quality audit support and port release.
  • Service capabilities: classification determination, registration and listing pathway selection, preparation and localisation of technical documentation (CSDT/STED), GMDN and grouping strategy, clinical evidence organisation, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fee and renewal management.
  • Contact: hito.lin@grzan.cn; website www.grzan.cn.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail